Cochlear Implant Lead Drug Release Using 3D Cochlea Profiles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional cochlear implant systems face challenges in delivering drugs optimally to address trauma and preserve residual hearing, as existing methods often result in suboptimal timing and location of drug release, leading to inflammation and fibrosis.
Innovation Solution
An individualized drug delivery profile is generated using a 3D cochlea model and procedure data to control the release of drugs from a stimulating lead, ensuring targeted distribution based on the recipient's cochlea shape and lead position, using electrical or optical stimulation to facilitate localized drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If drugs are passively released from the electrode lead into the perilymph, then the trauma can be treated, but the drugs are released at suboptimal timing and location
Solution Approach 1:
The patent applies dynamics by transitioning from passive, continuous drug release to active, controlled release. The system uses electrical stimulation to dynamically control drug release from the electrode lead, allowing precise timing and location control. The drug release is activated only when and where needed, transforming the static passive diffusion process into a dynamic controlled process that can be adjusted based on patient-specific requirements.
Solution Approach 2:
The patent applies local quality by enabling selective drug release at specific locations along the electrode lead rather than uniform release throughout. The system can target specific regions of the cochlea where trauma occurred, delivering concentrated drug doses locally. This allows different portions of the electrode lead to have different release characteristics, optimizing treatment effectiveness at trauma sites while minimizing unnecessary drug exposure elsewhere.
2Reliability
If repeated transtympanic administrations of anti-inflammatory drugs are performed, then intracochlear trauma can be treated, but off-target effects and patient burden increase
Solution Approach 1:
The patent applies the extraction principle by removing the drug delivery function from the general circulation system and concentrating it directly at the site of trauma within the cochlea. Instead of administering drugs systemically through the tympanic membrane and risking off-target effects, the system extracts and delivers drugs directly to the specific intracochlear location where trauma occurred, eliminating unnecessary systemic exposure and its associated harmful effects.
Solution Approach 2:
The patent uses the electrode lead as an intermediary carrier for drug delivery. Rather than relying on systemic circulation to transport drugs to the cochlea, the electrode lead serves as a direct intermediary pathway that delivers drugs precisely to the trauma site. This intermediary approach eliminates the need for repeated transtympanic administrations and their associated off-target effects, while maintaining effective trauma treatment.
3Reliability
If intracochlear administrations post-implantation are performed, then trauma can be treated, but damage to the implanted device and disruption of the local environment occur
Solution Approach 1:
The patent applies preliminary action by delivering drugs during the initial implantation procedure rather than after the device is already in place. The electrode lead is pre-loaded with drug reservoirs before insertion into the cochlea, allowing trauma treatment to begin immediately as the lead is being placed. This timing avoids the need for subsequent intracochlear interventions that could damage the implanted device or disrupt the healing environment.
Solution Approach 2:
The patent merges the drug delivery function with the electrode lead itself, combining the structural support function of the lead with the therapeutic drug delivery function. By integrating drug reservoirs into the electrode lead structure, the system eliminates the need for separate intracochlear drug administration procedures that could damage the device. The drug delivery mechanism becomes an inherent part of the implant rather than an add-on intervention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the preservation of intracochlear structures, reduces fibrosis, and increases the chances of preserving residual hearing, thereby extending the operational life and effectiveness of cochlear implants.
Implementation Method 1
release of a drug from the stimulating lead
Data Source
AI summary
An exemplary system comprises a memory that stores instructions and a processor communicatively coupled to the memory and configured to execute the instructions to perform a process. The process may comprise accessing an individual three-dimensional (“3D”) cochlea model of a cochlea of a recipient of a cochlear implant system that includes a stimulating lead inserted into the cochlea during a lead insertion procedure, generating, based on the individual 3D cochlea model and procedure data associated with one or more lead insertion procedures performed with respect to one or more other recipients, an individualized drug delivery profile for the recipient, and transmitting a command to the cochlear implant system to cause release of a drug from the stimulating lead in accordance with the individualized drug delivery profile.